Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden cancer hunt: Full-Body scan could spot tumors in blood clot patients

NCT ID NCT04304651

Diagnosis Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a detailed full-body scan called FDG PET/CT can find hidden cancers in people aged 50 and older who have had an unexplained blood clot. About 1,276 participants will get either the scan or standard cancer checks. The goal is to see if the scan catches more cancers early, which could lead to better treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG PET/CT scan
What this could lead to
If successful, this could show that advanced imaging like FDG PET/CT is better at catching hidden cancers early in people with unexplained blood clots, potentially improving survival.
What could go wrong
This is a diagnostic study, not a treatment trial. The scan may miss some cancers or lead to unnecessary follow-ups. Results may not apply to younger patients or those with provoked clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,276 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2020

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) will be eligible to participate into the study. Unprovoked VTE is defined as the absence of any of the following predisposing factors: 1. active malignancy (known malignancy, progressive and/or treated during the last 5 years) except for adequately treated basal or squamous cell carcinoma; Patients whose state of health suggests the presence of cancer at the time of diagnosis of VTE cannot be included in the protocol 2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower extremities; 3. recently bedridden for period of 3 or more days, or major surgery, within the previous 12 weeks requiring general or regional anaesthesia; 4. previous unprovoked VTE; 5. known thrombophilia (hereditary or acquired) Exclusion Criteria: Patients will be excluded from the study if they have any of the following criteria: 1. Refusal or inability to provide informed consent; 2. Hypersensitivity to 18F-FDG or any of the excipients according to the product monograph; 3. Unavailable to follow-up. 4. VTE while on anticoagulation (e.g apixaban, rivaroxaban, edoxaban, dabigatran, warfarin)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embolism and thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Embolism and Thrombosis pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embolism and thrombosis

Contacts and locations

Locations

  • Brest University Hospital

    Brest, France

  • CH Agen

    Agen, France

  • CH des Pays de Morlaix

    Morlaix, France, 29600, France

  • CHU Angers

    Angers, France

  • CHU Saint-Etienne

    Saint-Etienne, France

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France

  • CHU de Dijon

    Dijon, France

  • CHU de Limoges

    Limoges, France

  • Hopital Montfort

    Ottawa, Ontario, Canada

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Hôpital Saint Musse - CH Toulon

    Toulon, France

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Sherbrooke Hospital

    Sherbrooke, Canada

  • Sunnybrook Research Institute

    Toronto, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.